×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Bullish Sarepta Therapeutics Insiders Loaded Up On US$13.3m Of Stock
Yahoo Finance
Multiple insiders secured a larger position in Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shares over the last 12...
2 days ago
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Business Wire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024...
3 days ago
US FDA to review Sarepta's Duchenne gene therapy for traditional approval
Reuters
Sarepta Therapeutics said on Friday that the US FDA would review an application seeking traditional approval for its gene therapy to treat a...
2 months ago
Sarepta’s Duchenne Gene Therapy Elevidys Nabs $200M on Strong Demand
BioSpace
Sarepta Therapeutics on Wednesday called the launch of the gene therapy for Duchenne muscular dystrophy “exceptional” but the company does...
1 month ago
State's highest paid CEO reports major drop in compensation - Boston Business Journal
The Business Journals
The highest-paid chief executive in Massachusetts in 2022 will likely drop completely off the rankings for 2023 based on data from his...
2 days ago
This Is What Whales Are Betting On Sarepta Therapeutics - Sarepta Therapeutics (NASDAQ:SRPT)
Benzinga
High-rolling investors have positioned themselves bullish on Sarepta Therapeutics. SRPT+1.16%. + Free Alerts.
3 days ago
FDA's Peter Marks seems inclined to grant full approval to Sarepta's Duchenne gene therapy
STAT
At an event on the sidelines of the J.P. Morgan Healthcare Conference, Marks seemed comfortable with granting some form of full approval to...
3 months ago
Sarepta Stock Takes A Beating; And It Might Not Be Over
Investor's Business Daily
Sarepta stock has a promising Composite Rating of 91, according to IBD Digital. This means shares rank in the top 9% of all stocks in terms of...
3 weeks ago
Sarepta Shares Soar After Muscle Therapy Gets Broader FDA Review
Bloomberg
Sarepta Therapeutics Inc. shares soared after US regulators granted a speedy review to an application to expand its gene therapy to older...
2 months ago
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
The Motley Fool
I continue to be immensely proud of our mission-driven team. Combining our PMO and gene therapy businesses, we exceeded a billion in net product...
1 month ago